14 unknown, 12 completed, 12 recruiting, 6 terminated. 12 Phase 2, 10 Not applicable, 5 Phase 1, 4 Phase 3, 4 Phase 4.
Follow Graft Failure: new trials by email Literature Review of Graft Failure trials Research Report on Graft Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Differences in Outcomes and Failure Rates Between Allografts and Autografts in Revision Anterior Cruciate Ligament Reconstruction ACL Injury, Graft Failure | Recruiting | Stefano Zaffagnini | 150 | 2026-07-08 | 2026-08-04 | |
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients Emapalumab 3 mg/kg, Emapalumab 10 mg/kg - Hematopoietic Stem Cell Transplantation, Graft Failure | Early Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 20 | 2026-01-07 | 2026-01-22 |
| Pilot Trial of Colchicine for Graft Failure in CABG Colchicine - CABG, Graft Failure | Phase 4 | Active not recruiting | Ruijin Hospital | 100 | 2025-12-29 | 2026-10-27 |
| Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG Oral isosorbide mononitrate 4+ amlodipine - Coronary Artery Bypass Graft Surgery (CABG), Radial Artery Grafts | Phase 4 | Withdrawn | Ruijin Hospital | 2025-06-01 | 2025-09-17 | |
| Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients Protein A immunoadsorption, Rituximab (optional, in some patients), Bortezomib (optional, in some patients) - Hematologic Malignancies, Hematologic Disorders | Completed | Ting YANG | 50 | 2025-05-31 | 2025-11-18 | |
| Graft Failure and Consequences of Coronary Artery Bypass Graft Surgery Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography - Coronary Artery Bypass, Graft Failure | Recruiting | University of Edinburgh | 70 | 2025-03-28 | 2026-04-20 | |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure CD34+ Selected Donor Cell Boost, Blood Stem Cell Infusion - Graft Failure, Poor Graft Function | Not applicable | Recruiting | NYU Langone Health | 21 | 2024-10-31 | 2026-08-17 |
| Modified Second Haplo-transplantation for Graft Failure second allogeneic stem cell transplantation - Graft Failure, Stem Cell Transplant Complications | Not applicable | Recruiting | Peking University People's Hospital | 12 | 2024-07-01 | 2024-11-29 |
| Second Haplo-transplantation for Graft Failure second allogeneic stem cell transplantation - Graft Failure, Stem Cell Transplant Complications | Not applicable | Recruiting | Peking University People's Hospital | 34 | 2024-07-01 | 2024-11-07 |
| Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure Continue low dose calcineurin inhibitor (CNI), Calcineurin inhibitor withdrawal at 6 months - Renal Failure , Chronic, Graft Failure | Phase 4 | Recruiting | Hospital Universitari Vall d'Hebron Research Institute | 202 | 2024-01-22 | 2024-11-06 |
| Factors for Impairment of Renal Graft Function in Intensive Care Graft Failure, Dialysis | Unknown | Central Hospital, Nancy, France | 200 | 2024-01-01 | 2024-02-08 | |
| One-year Patency Comparison Between Radial Artery and No-touch Saphenous Vein Grafts in Women Undergoing Isolated CABG Coronary artery bypass graft - Cardiac Disease, Surgery-Complications | Not applicable | Recruiting | University of Sao Paulo General Hospital | 150 | 2024-01-01 | 2025-12-12 |
| Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis WJ-MSC infusion - Allogeneic Disease, GVHD,Acute | Phase 1 | Unknown | Central Hospital, Nancy, France | 12 | 2023-09-01 | 2023-05-11 |
| Study of the No-touch Saphenous Vein Graft Сoronary bypass surgery according to the I-graft method, Сoronary bypass surgery by the method of free conduit - Coronary Artery Disease, Coronary Artery Stenosis | Not applicable | Unknown | Meshalkin Research Institute of Pathology of Circulation | 106 | 2022-12-22 | 2024-02-08 |
| Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure haplo-SCT with PTCy - Hematologic Diseases, Graft Failure | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 35 | 2021-12-01 | 2021-11-18 |
| Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy Tocilizumab - Kidney Transplantation, Graft Failure | Phase 2 | Completed | University Hospital, Toulouse | 18 | 2021-10-01 | 2025-12-31 |
| Tumescence in HNC Skin Graft Reconstruction Tumescence During STSG Harvest - Head and Neck Cancer, Surgery--Complications | Phase 3 | Active not recruiting | University of California, Davis | 58 | 2021-09-01 | 2026-02-18 |
| Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT. Emapalumab - Graft Failure | Phase 2 | Terminated | Swedish Orphan Biovitrum | 2 | 2021-05-25 | 2023-12-28 |
Showing 20 of 51. Sign in to see all of them.
Coronary Artery Disease (3) · Hematologic Diseases (3) · Kidney Failure, Chronic (3) · Acute Kidney Injury (2) · Anemia, Sickle Cell (2) · Death (2) · Delayed Graft Function (2) · Heart Diseases (2) · Renal Insufficiency, Chronic (2) · Reperfusion Injury (2) · Aneurysm (1) · Angina Pectoris (1) · Anterior Cruciate Ligament Injuries (1) · Bone Diseases (1) · Brain Death (1)
Pathological Conditions, Signs and Symptoms (12) · Pathologic Processes (11) · Cardiovascular Diseases (9) · Vascular Diseases (9) · Hemic and Lymphatic Diseases (7) · Chronic Disease (5) · Disease Attributes (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Myocardial Ischemia (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Heart Diseases (4)
Tacrolimus (4) · Mycophenolic Acid (3) · fludarabine (3) · Alemtuzumab (2) · Emapalumab (2) · plerixafor (2) · Blood Specimen Collection (1) · Blood Vessel Prosthesis (1) · Bortezomib (1) · Busulfan (1) · Calcineurin Inhibitors (1) · Colchicine (1) · Coronary Artery Bypass (1) · Coronary Artery Bypass, Off-Pump (1) · Cyclophosphamide (1)
Peking University People's Hospital (3) · Assistance Publique - Hôpitaux de Paris (2) · Central Hospital, Nancy, France (2) · Policlinico Hospital (2) · Ruijin Hospital (2) · Swedish Orphan Biovitrum (2) · University of Edinburgh (2) · University of Sao Paulo General Hospital (2) · Amsterdam UMC, location VUmc (1) · Arkansas Children's Hospital Research Institute (1) · Asan Medical Center (1) · B. Braun Melsungen AG (1) · Baylor College of Medicine (1) · Baylor Research Institute (1) · Beijing Anzhen Hospital (1)
United States (12) · China (8) · France (5) · Italy (4) · Germany (3) · United Kingdom (3) · Brazil (2) · Canada (2) · Netherlands (2) · Russia (2) · Australia (1) · Belgium (1) · Israel (1) · Kuwait (1) · Portugal (1)
Franco Valenza, MD (2) · Qiang Zhao, MD (2) · Xiao-Jun Huang, M.D. (2) · Yunpeng Zhu, MD (2) · Alexei Maschan, Professor (1) · Alicja Zientara, Dr (1) · Anthony Sabulski, MD (1) · Ashvind Prabahran, Dr (1) · Chirag R Parikh, MD PhD (1) · Clara IC Azevedo, MD (1) · David Kluth, PhD (1) · Dmitry Balashov (1) · Dmitry Khvan, Ph.D. (1) · Elias David-Neto, PhD (1)
PMID 15367224, PMID 16115856, PMID 16186274, PMID 16597636, PMID 16998222, PMID 17220787, PMID 17314207, PMID 17876282, PMID 18165774, PMID 18217144, PMID 18698241, PMID 19104410, PMID 19352130, PMID 19461495, PMID 19623026, PMID 19696640, PMID 19951280, PMID 20029338, PMID 20559032, PMID 21372213, PMID 21458900, PMID 21659736, PMID 21685828, PMID 22037739, PMID 22054202, PMID 22716194, PMID 23064656, PMID 23378624, PMID 23497558, PMID 23929933, PMID 24558049, PMID 24612768, PMID 24628890, PMID 25154787, PMID 25361179, PMID 25453995, PMID 25710609, PMID 25739949, PMID 26091179, PMID 26319244, PMID 26680374, PMID 26844883, PMID 27107804, PMID 27451287, PMID 27500266, PMID 27696386, PMID 28461454, PMID 28490533, PMID 28494514, PMID 28574431
2023 (2), 2018 (1), R01DK093770 (1)